Other languages BeiGene, Ltd.

Equities

BGNE

US07725L1026

Real-time Estimate Cboe BZX Other stock markets 12:35:48 2024-05-13 pm EDT			5-day change	1st Jan Change
164 ^USD	+1.78%		+1.03%	-8.99%

May. 09	Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	MT
May. 08	Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle Geschäftsentwicklungen	May. 09
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	May. 08
BeiGene presenta los resultados financieros del primer trimestre de 2024 y actualiza sus actividades	May. 08
BeiGene présente ses résultats financiers du premier trimestre 2024 et ses dernières nouvelles commerciales	May. 08
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08
BeiGene's Q1 Loss Narrows as Revenue Rises	May. 08
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024	May. 08
Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	Apr. 25
BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024	Apr. 25
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	Apr. 23
BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules	Apr. 23
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10
Beigene Shrinks Loss by 56% in 2023	Mar. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeiGene, Ltd.

Equities

BGNE

US07725L1026

Other languages

Filters